Latest market price
3.14
+0.08+2.61%
OverviewShort InterestFilings
LXEOQT11Lexeo Therapeutics, Inc. Common Stock·NASDAQ
3.14+2.61%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
TRAX-0.33%$45.08NVAX-3.72%$10.08NUVB-0.21%$4.76KLRA-4.10%$12.86REPL+1.27%$17.61STOK-0.23%$26.29QURE-1.86%$24.83NTLA-5.74%$12.47
Snapshot
Index—P/E—EPS (ttm)-1.15Insider Own10.95%Shs Outstand82.09MPerf Week12.14%
Market Cap257.76MForward P/E—EPS next Y-1.34Insider Trans-0.79%Shs Float51.21MPerf Month-13.26%
Enterprise Value49.76MPEG—EPS next Q-0.32Short Float34.27%Perf Quarter-25.24%
Income-87.00MP/S—EPS this Y—Short Ratio13.96Perf Half Y-45.58%
Sales0.00P/B1.10EPS next Y—ROA-34.24%Short Interest17.55MPerf YTD-68.38%
Book/sh2.86P/C1.22EPS next 5Y—ROE-41.85%52W High10.99 -71.43%Perf Year-68.31%
Cash/sh2.58P/FCF—EPS past 3/5Y—ROIC-39.33%52W Low2.55 23.14%Perf 3Y—
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility10.45% 8.42%Perf 5Y—
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)0.27Perf 10Y—
Dividend Ex-Date—Quick Ratio13.89Sales Y/Y TTM—Profit Margin0.00%RSI (14)48.26Recom2.00
Dividend Gr. 3/5Y—Current Ratio13.89EPS Q/Q50.00%SMA205.30%Beta1.96Target Price21.13
Payout0.00%Debt/Eq0.02Sales Q/Q—SMA50-16.31%Rel Volume0.76Prev Close3.06
Employees63LT Debt/Eq0.02EarningsDec 14SMA200-39.75%Avg Volume1.31MPrice3.14
IPO DateNov 03, 2023Option/ShortYes / YesEPS/Sales Surpr.-5.20% —Net Debt/EBITDA—Volume1,001,519Change2.61%
Analyst Ratings
DateActionAnalystRatingTarget
Jan-13-26ReiteratedHC Wainwright & Co.Buy$13 → $10
Dec-17-25InitiatedRaymond JamesStrong Buy
Dec-10-25ReiteratedOppenheimer$20
Nov-20-25InitiatedCantor FitzgeraldOverweight$19
Oct-21-25ReiteratedHC Wainwright & Co.Buy$15 → $13
Oct-15-25InitiatedGuggenheimBuy
Oct-07-25ReiteratedHC Wainwright & Co.Buy$15
Oct-07-25ReiteratedChardan CapitalBuy$17
Oct-07-25ReiteratedLeerink PartnersOutperform$20
Jun-12-24InitiatedBairdOutperform
Latest News· Times ET
Oct-25-26
Oct-25-2610:02AM
Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readoutmarketbeat.com
Oct-24-26
Oct-24-2603:15PM
Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy - SlideshowSeekingAlpha
03:02AM
Lexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene Therapymarketbeat.com
Oct-21-26
Oct-21-2607:54PM
Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy Transcriptseekingalpha.com
Oct-19-26
Oct-19-2607:00AM
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACMglobenewswire.com
Oct-08-26
Oct-08-2607:00AM
Lexeo Therapeutics to Participate in the Chardan Healthcare Conferenceglobenewswire.com
Oct-01-26
Oct-01-2609:00AM
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson's Disease and Movement Disorders 2026 (MDS)globenewswire.com
Sep-23-26
Sep-23-2608:00AM
Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich AtaxiaYahoo
07:00AM
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forumglobenewswire.com
Sep-22-26
Sep-22-2601:49PM
Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcriptseekingalpha.com
07:00AM
Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxiaglobenewswire.com
Sep-03-26
Sep-03-2603:50AM
BlackRock Inc. Takes Position in Lexeo Therapeutics, Inc. $LXEOdefenseworld.net
Sep-02-26
Sep-02-2607:00AM
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in Septemberglobenewswire.com
Aug-27-26
Aug-27-2603:55AM
1,489,189 Shares in Lexeo Therapeutics, Inc. $LXEO Acquired by Avoro Capital Advisors LLCdefenseworld.net
Aug-12-26
Aug-12-2607:00AM
Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlightsglobenewswire.com
Company

Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
Total Revenue
0000———
Cost of Goods Sold Incl. D&A
1000———
Gross Profit
-1000———
Selling, General and Administrative Excl. Other29453215———
Research and Development67647453———
Other Operating Expense-1001———
Operating Income-95-109-106-69———
Interest Expense
0000———
Unusual Expense
———————
Non-Operating Income (Expense)71082———
Net Income Before Taxes-87-100-98-66———
Income Taxes
0000———
Consolidated Net Income-87-100-98-66———
Net Income From Continuing Operations-87-100-98-66———
Net Income-87-100-98-66———
EPS (Recurring)-1.15-1.86-3.09-2.49———
EPS (Basic, Before Extraordinaries)-1.15-1.86-3.09-2.49———
EPS (Diluted)-1.15-1.86-3.09-2.49———
EBITDA-85-98-96-64———
Other After Tax Adjustments
———————
Stock Option Compensation Expense
———————
Price To Earnings Ratio
———————
Price To Sales Ratio
———————
Gross Margin
———————
Operating Margin
———————
Net Margin
———————
Shares Outstanding86543227———
Market Capitalization270536211362———
Operating Lease Expense
———————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$11.83$9.23$6.63$4.03$1.43● Close Price0.00K78.28K156.57K234.85K313.14KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Otero Jose ManuelChief Operating OfficerAug 18 '26Sale4.961,3046,464136,178Aug 19
Tamayo Louis EdwardChief Financial OfficerAug 18 '26Sale4.914,11720,20392,907Aug 19
Townsend Richard NolanChief Executive OfficerAug 18 '26Sale4.953,34516,562374,472Aug 19
Tamayo Louis EdwardChief Financial OfficerJul 01 '26Sale4.494,64120,83897,024Jul 01
Bhalla Narinder PalChief Medical OfficerJul 01 '26Sale4.4222,30698,59382,194Jul 01
Otero Jose ManuelChief Operating OfficerJul 01 '26Sale4.484,66620,904137,482Jul 01
Townsend Richard NolanChief Executive OfficerJul 01 '26Sale4.4825,947116,243377,817Jul 01
Otero Jose ManuelChief Operating OfficerMay 18 '26Sale5.071,3026,606130,088May 20
Townsend Richard NolanChief Executive OfficerMay 18 '26Sale5.063,34216,927336,764May 20
Townsend Richard NolanChief Executive OfficerApr 06 '26Sale5.6955,000313,137340,106Apr 07
Otero Jose ManuelChief Operating OfficerFeb 18 '26Sale6.403,01619,294125,460Feb 20
Townsend Richard NolanChief Executive OfficerFeb 18 '26Sale6.3810,17364,924392,483Feb 20
Otero Jose ManuelChief Operating OfficerNov 18 '25Sale9.277216,68463,476Feb 20
Adler EricChief Medical OfficerNov 18 '25Sale9.276155,70172,646Nov 20
Robertson JennyChief Legal OfficerNov 18 '25Sale9.275495,08968,381Nov 20
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.